Table 4 Comparison of baseline and post-treatment variables in the CHC patients with and without an SVR after propensity score matching.

HCV-RNA, log IU/mL

5.84(4.66–6.66)

0

<0.001^b

6.19(4.64–6.64)

4.69(3.23–6.06)

<0.001^b

FPG, mmol/L

5.35(4.99–5.98)

5.14(4.81–5.62)

0.027^b

5.33(5.02–5.83)

5.42(4.91–5.96)

0.723

TBiL, umol/L

15.1(11.2–21.2)

13.60(9.6–18.1)

0.055

15.6(10.9–21.4)

12.7(9.4–19)

0.037^b

ALT, IU/L

54(29–97)

20 (14–31)

<0.001^b

47(27–84)

35(19–68)

0.049^b

AST, IU/L

42(31–74)

25(21–33)

<0.001^b

42(30–76)

34(26–58)

0.023^b

ALB, g/L

44.4(41.3–46.8)

45.8(43.4–47.6)

0.004^b

43.2(40.80–45.4)

45.3(42.7–47.3)

0.001^b

ALP, IU/L

83(68–106)

78(62–92)

0.050

86(71–105)

86(72–100)

0.579

GGT, IU/L

36(24–67)

20(14–35)

<0.001^b

38(20–78)

31(20–56)

0.105

Hb, g/L

142(125–153)

141(117–151)

0.407

131(111–142)

130(111–148)

0.958

PLTs, 10⁹/L

128(96–172)

138(103–174)

0.356

111(72–157)

120(86–172)

0.273

WBCs, 10⁹/L

5.24(4.14–6.9)

5.75(3.86–7.3)

0.443

4.35(3.46–5.67)

4.49(3.43–6)

0.310

APRI

0.91(0.55–1.63)

0.49(0.33–0.76)

<0.001^b

1.17(0.55–2.21)

0.71(0.48–1.37)

0.020^b

FIB-4

2.33(1.52–4.13)

2.13(1.38–3.24)

0.126

2.69(1.73–5.33)

2.43(1.49–4.07)

0.244